Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Share-based Compensation: 2016-2025

Historic Share-based Compensation for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Sep 2025 value amounting to $18.8 million.

  • Rhythm Pharmaceuticals' Share-based Compensation rose 70.98% to $18.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.1 million, marking a year-over-year increase of 53.72%. This contributed to the annual value of $39.7 million for FY2024, which is 21.90% up from last year.
  • Rhythm Pharmaceuticals' Share-based Compensation amounted to $18.8 million in Q3 2025, which was up 18.45% from $15.9 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' 5-year Share-based Compensation high stood at $18.8 million for Q3 2025, and its period low was $4.6 million during Q1 2022.
  • Moreover, its 3-year median value for Share-based Compensation was $10.4 million (2024), whereas its average is $10.9 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first declined by 11.17% in 2022, then surged by 79.57% in 2023.
  • Over the past 5 years, Rhythm Pharmaceuticals' Share-based Compensation (Quarterly) stood at $4.7 million in 2021, then rose by 13.07% to $5.3 million in 2022, then skyrocketed by 64.06% to $8.7 million in 2023, then climbed by 21.70% to $10.6 million in 2024, then surged by 70.98% to $18.8 million in 2025.
  • Its Share-based Compensation stands at $18.8 million for Q3 2025, versus $15.9 million for Q2 2025 and $12.9 million for Q1 2025.